


SU4984

Cat. No.:	HY-118203
CAS No.:	186610-89-9
Molecular Formula:	C ₂₀ H ₁₉ N ₃ O ₂
Molecular Weight:	333.38
Target:	FGFR; Insulin Receptor; PDGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (149.98 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.9996 mL	14.9979 mL	29.9958 mL
				5 mM	0.5999 mL	2.9996 mL	5.9992 mL
				10 mM	0.3000 mL	1.4998 mL	2.9996 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (15.00 mM); Suspended solution; Need ultrasonic						

BIOLOGICAL ACTIVITY

Description	SU4984 is a protein tyrosine kinase inhibitor, with an IC ₅₀ of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer ^{[1][2][3]} .
IC ₅₀ & Target	FGFR1 10-20 μM (IC ₅₀)
In Vitro	SU4984 (5-100 μM; 5 min) inhibits the kinase activity of FGFR1K with an IC ₅₀ of 10-20 μM in the presence of 1 mM adenosine triphosphate (ATP) ^[1] . SU4984 (10-90 μM; 5 min) inhibits the autophosphorylation of FGFR1 induced by aFGF in NIH 3T3 cells, with an IC ₅₀ of 20-40 μM ^[1] . SU4984 (5 μM) substantially reduces tyrosine phosphorylation of the wild-type receptor and reduces 50% phosphorylation of constitutive C2 KIT ^[2] . SU4984 (1-10 μM; 6 days) kills the C2 and P815 cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Mohammadi M, et, al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. *Science*. 1997 May 9;276(5314):955-60.
- [2]. Ma Y, et, al. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. *J Invest Dermatol*. 2000 Feb;114(2):392-4.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA